Markus Warmuth - 23 Jun 2021 Form 3 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
President & Chief Executive Officer Exhibit 24 - Power of Attorney, Director
Signature
/s/ Ajim Tamboli, Attorney-in-Fact
Issuer symbol
GLUE
Transactions as of
23 Jun 2021
Net transactions value
$0
Form type
3
Filing time
23 Jun 2021, 20:38:19 UTC
Previous filing
25 Jun 2021
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding GLUE Common Stock 416,538 23 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GLUE Stock Option (Right to Buy) 23 Jun 2021 Common Stock 786,756 $2.19 Direct F2
holding GLUE Stock Option (Right to Buy) 23 Jun 2021 Common Stock 538,517 $6.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amount consists of shares of restricted stock subject to vesting. As of the date hereof, 182,236 shares have vested and 234,302 shares remain unvested.
F2 25% of this option shall vest and become exercisable on December 4, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter.
F3 25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

President & Chief Executive Officer Exhibit 24 - Power of Attorney